Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Recruiting

95 enrolled

Breast

Breast Neoplasms

NCT06993844 2026-03-17

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

233 enrolled

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

792 enrolled

Breast

Breast Neoplasms

NCT06736704 2026-03-13

SNV4818 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

320 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT07287917 2026-03-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Phase 1/2 Recruiting

92 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT05768139 2026-03-02

PIKALO-1

Phase 1/2 Recruiting

720 enrolled

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07288359 2026-02-23

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1/2 Recruiting

205 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04115306 2026-01-21

Dauntless-1

Phase 1/2 Recruiting

61 enrolled

Breast

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05608252 2025-10-29

VS-6766+Abema+Fulv in Met HR+/HER- BC

Phase 1/2 Recruiting

63 enrolled

Breast

Breast Neoplasms

NCT06208410 2025-07-25

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Phase 1/2 Recruiting

306 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06555068 2025-06-22

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

Phase 1/2 Recruiting

528 enrolled

Breast

Breast Neoplasms

NCT05319873 2025-05-13

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Recruiting

18 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT04282031 2024-08-07

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Phase 1/2 Recruiting

224 enrolled

BreastOther solid neoplasm

Advanced Solid Tumor

NCT04092673 2024-05-21

Zotatifin

Phase 1/2 Recruiting

30 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT06202261 2024-03-12

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Phase 1/2 Recruiting

154 enrolled

Breast

Breast Neoplasms

Clinical Trials

AVZO-023-1001

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

INX-315-01

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Morpheus-panBC

SNV4818 in Participants With Advanced Solid Tumors

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

PIKALO-1

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Dauntless-1

Study of AVZO-021 in Patients With Advanced Solid Tumors

VS-6766+Abema+Fulv in Met HR+/HER- BC

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Zotatifin

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer